TISIDB

Summary
Symbol	PMEPA1
Name	prostate transmembrane protein, androgen induced 1
Aliases	solid tumor-associated 1; TMEPAI; transmembrane, prostate androgen induced RNA; prostate transmembrane prote ......
Chromosomal Location	20q13.31-q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Early endosome membrane; Single-pass membrane protein. Golgi apparatus membrane; Single-pass membrane protein.
Domain	-
Function	Functions as a negative regulator of TGF-beta signaling and thereby probably plays a role in cell proliferation, differentiation, apoptosis, motility, extracellular matrix production and immunosuppression. In the canonical TGF-beta pathway, ZFYVE9/SARA recruits the intracellular signal transducer and transcriptional modulators SMAD2 and SMAD3 to the TGF-beta receptor. Phosphorylated by the receptor, SMAD2 and SMAD3 then form a heteromeric complex with SMAD4 that translocates to the nucleus to regulate transcription. Through interaction with SMAD2 and SMAD3, LDLRAD4 may compete with ZFYVE9 and SMAD4 and prevent propagation of the intracellular signal (PubMed:20129061, PubMed:24627487). Also involved in down-regulation of the androgen receptor (AR), enhancing ubiquitination and proteasome-mediated degradation of AR, probably by recruiting NEDD4 (PubMed:18703514).

> Gene Ontology [ TOP ]
Biological Process	GO:0001933 negative regulation of protein phosphorylation GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway GO:0007179 transforming growth factor beta receptor signaling pathway GO:0007183 SMAD protein complex assembly GO:0009755 hormone-mediated signaling pathway GO:0010990 regulation of SMAD protein complex assembly GO:0010991 negative regulation of SMAD protein complex assembly GO:0017015 regulation of transforming growth factor beta receptor signaling pathway GO:0030512 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030518 intracellular steroid hormone receptor signaling pathway GO:0030521 androgen receptor signaling pathway GO:0030522 intracellular receptor signaling pathway GO:0031333 negative regulation of protein complex assembly GO:0042326 negative regulation of phosphorylation GO:0043254 regulation of protein complex assembly GO:0043401 steroid hormone mediated signaling pathway GO:0048545 response to steroid hormone GO:0060389 pathway-restricted SMAD protein phosphorylation GO:0060393 regulation of pathway-restricted SMAD protein phosphorylation GO:0060394 negative regulation of pathway-restricted SMAD protein phosphorylation GO:0071383 cellular response to steroid hormone stimulus GO:0071396 cellular response to lipid GO:0071407 cellular response to organic cyclic compound GO:0071559 response to transforming growth factor beta GO:0071560 cellular response to transforming growth factor beta stimulus GO:0090092 regulation of transmembrane receptor protein serine/threonine kinase signaling pathway GO:0090101 negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway GO:0090287 regulation of cellular response to growth factor stimulus GO:0090288 negative regulation of cellular response to growth factor stimulus GO:1903844 regulation of cellular response to transforming growth factor beta stimulus GO:1903845 negative regulation of cellular response to transforming growth factor beta stimulus
Molecular Function	GO:0046332 SMAD binding GO:0050699 WW domain binding GO:0070412 R-SMAD binding
Cellular Component	GO:0005769 early endosome GO:0010008 endosome membrane GO:0031901 early endosome membrane GO:0044440 endosomal part

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-2173788: Downregulation of TGF-beta receptor signaling R-HSA-162582: Signal Transduction R-HSA-170834: Signaling by TGF-beta Receptor Complex R-HSA-2173789: TGF-beta receptor signaling activates SMADs

Summary
Symbol	PMEPA1
Name	prostate transmembrane protein, androgen induced 1
Aliases	solid tumor-associated 1; TMEPAI; transmembrane, prostate androgen induced RNA; prostate transmembrane prote ......
Chromosomal Location	20q13.31-q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between PMEPA1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	PMEPA1
Name	prostate transmembrane protein, androgen induced 1
Aliases	solid tumor-associated 1; TMEPAI; transmembrane, prostate androgen induced RNA; prostate transmembrane prote ......
Chromosomal Location	20q13.31-q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of PMEPA1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	PMEPA1
Name	prostate transmembrane protein, androgen induced 1
Aliases	solid tumor-associated 1; TMEPAI; transmembrane, prostate androgen induced RNA; prostate transmembrane prote ......
Chromosomal Location	20q13.31-q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of PMEPA1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-1.228	0.016
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.396	0.421
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-1.112	0.434
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.106	0.829
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.391	0.831
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.717	0.793
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.464	0.407
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.267	0.861
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.763	0.633
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.842	0.617
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.98	0.41
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.468	0.0186

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of PMEPA1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	14.3	5.9	8.4	0.613
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	9.1	6.3	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	22.2	6.2	16	0.53
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	11.1	8.9	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	11.1	-11.1	0.067
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	7.7	-7.7	0.371
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	14.3	-14.3	0.209
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	PMEPA1
Name	prostate transmembrane protein, androgen induced 1
Aliases	solid tumor-associated 1; TMEPAI; transmembrane, prostate androgen induced RNA; prostate transmembrane prote ......
Chromosomal Location	20q13.31-q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PMEPA1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	PMEPA1
Name	prostate transmembrane protein, androgen induced 1
Aliases	solid tumor-associated 1; TMEPAI; transmembrane, prostate androgen induced RNA; prostate transmembrane prote ......
Chromosomal Location	20q13.31-q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PMEPA1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PMEPA1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	PMEPA1
Name	prostate transmembrane protein, androgen induced 1
Aliases	solid tumor-associated 1; TMEPAI; transmembrane, prostate androgen induced RNA; prostate transmembrane prote ......
Chromosomal Location	20q13.31-q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PMEPA1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	PMEPA1
Name	prostate transmembrane protein, androgen induced 1
Aliases	solid tumor-associated 1; TMEPAI; transmembrane, prostate androgen induced RNA; prostate transmembrane prote ......
Chromosomal Location	20q13.31-q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of PMEPA1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	PMEPA1
Name	prostate transmembrane protein, androgen induced 1
Aliases	solid tumor-associated 1; TMEPAI; transmembrane, prostate androgen induced RNA; prostate transmembrane prote ......
Chromosomal Location	20q13.31-q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between PMEPA1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	PMEPA1
Name	prostate transmembrane protein, androgen induced 1
Aliases	solid tumor-associated 1; TMEPAI; transmembrane, prostate androgen induced RNA; prostate transmembrane prote ......
Chromosomal Location	20q13.31-q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting PMEPA1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse PMEPA1